NASDAQ:VYNE

VYNE Therapeutics Stock Forecast, Price & News

$2.70
0.00 (0.00 %)
(As of 07/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.64
$2.81
50-Day Range
$2.69
$4.11
52-Week Range
$2.62
$13.20
Volume306,994 shs
Average Volume584,226 shs
Market Capitalization$138.75 million
P/E RatioN/A
Dividend YieldN/A
Beta0.75
30 days | 90 days | 365 days | Advanced Chart
Receive VYNE News and Ratings via Email

Sign-up to receive the latest news and ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


VYNE Therapeutics logo

About VYNE Therapeutics

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.51 out of 5 stars

Medical Sector

1195th out of 4,434 stocks

Pharmaceutical Preparations Industry

577th out of 1,738 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











VYNE Therapeutics (NASDAQ:VYNE) Frequently Asked Questions

Is VYNE Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VYNE Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VYNE Therapeutics stock.
View analyst ratings for VYNE Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than VYNE Therapeutics?

Wall Street analysts have given VYNE Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but VYNE Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting VYNE Therapeutics?

VYNE Therapeutics saw a decrease in short interest in June. As of June 30th, there was short interest totaling 2,570,000 shares, a decrease of 35.6% from the June 15th total of 3,990,000 shares. Based on an average trading volume of 924,700 shares, the short-interest ratio is presently 2.8 days. Currently, 5.1% of the company's shares are short sold.
View VYNE Therapeutics' Short Interest
.

When is VYNE Therapeutics' next earnings date?

VYNE Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for VYNE Therapeutics
.

How were VYNE Therapeutics' earnings last quarter?

VYNE Therapeutics Inc. (NASDAQ:VYNE) posted its earnings results on Thursday, May, 6th. The company reported ($0.37) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.47) by $0.10. The business had revenue of $4.12 million for the quarter, compared to the consensus estimate of $5.08 million. VYNE Therapeutics had a negative trailing twelve-month return on equity of 375.26% and a negative net margin of 1,009.70%.
View VYNE Therapeutics' earnings history
.

How has VYNE Therapeutics' stock price been impacted by Coronavirus?

VYNE Therapeutics' stock was trading at $13.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VYNE shares have decreased by 79.5% and is now trading at $2.70.
View which stocks have been most impacted by COVID-19
.

When did VYNE Therapeutics' stock split? How did VYNE Therapeutics' stock split work?

VYNE Therapeutics's stock reverse split on Tuesday, February 16th 2021. The 1-4 reverse split was announced on Thursday, February 11th 2021. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 15th 2021. An investor that had 100 shares of VYNE Therapeutics stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for VYNE?

5 analysts have issued 12 month target prices for VYNE Therapeutics' stock. Their forecasts range from $11.00 to $28.00. On average, they expect VYNE Therapeutics' stock price to reach $21.00 in the next year. This suggests a possible upside of 677.8% from the stock's current price.
View analysts' price targets for VYNE Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are VYNE Therapeutics' key executives?

VYNE Therapeutics' management team includes the following people:
  • Mr. David T. Domzalski, CEO, Pres & Director (Age 54, Pay $907.72k)
  • Ms. Mutya Harsch, Gen. Counsel, Chief Legal Officer & Company Sec. (Age 46, Pay $523.26k)
  • Mr. Tyler Zeronda, Interim CFO, Principal Accounting Officer & Treasurer (Age 35)
  • Dr. Iain A. Stuart, Chief Scientific Officer (Age 48)
  • Mr. Raymond G. Steitz, Sr. VP of Global HR (Age 62)
  • Dr. Russell Elliott, Sr. VP of Pharmaceutical Devel. (Age 55)
  • Mr. Matthew Wiley, Chief Commercial Officer (Age 49)
  • Dr. Darrell S. Rigel M.S., M.D., MS, Consultant (Age 71)

Who are some of VYNE Therapeutics' key competitors?

What other stocks do shareholders of VYNE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VYNE Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), OrganiGram (OGI), Zosano Pharma (ZSAN), KushCo (KSHB), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS).

What is VYNE Therapeutics' stock symbol?

VYNE Therapeutics trades on the NASDAQ under the ticker symbol "VYNE."

How do I buy shares of VYNE Therapeutics?

Shares of VYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VYNE Therapeutics' stock price today?

One share of VYNE stock can currently be purchased for approximately $2.70.

How much money does VYNE Therapeutics make?

VYNE Therapeutics has a market capitalization of $138.75 million and generates $20.99 million in revenue each year. The company earns $-255,570,000.00 in net income (profit) each year or ($7.88) on an earnings per share basis.

How many employees does VYNE Therapeutics have?

VYNE Therapeutics employs 106 workers across the globe.

What is VYNE Therapeutics' official website?

The official website for VYNE Therapeutics is www.menlotherapeutics.com.

Where are VYNE Therapeutics' headquarters?

VYNE Therapeutics is headquartered at 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807.

How can I contact VYNE Therapeutics?

VYNE Therapeutics' mailing address is 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807. The company can be reached via phone at 800-775-7936 or via email at [email protected]


This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.